ShangPharma to Build $60 Million Biologics Campus

ShangPharma, a Shanghai CRO/CMO, will partner with Qidong Biopharma Industrial Zone to build a $60 million biologics campus, including an R&D facility and state-of-the-art manufacturing plant. The two facilities comprise the first stage in a project that is expected to include multiple phases. ShangPharma's CRO division, ChemPartner, will be responsible for the R&D operation while ShangPharma's CMO division, China Gateway Biologics, will be in charge of the commercial scale manufacturing facility. ShangPharma expects the manufacturing plant to be ready for client projects in 2018. More details.... Share this with colleagues: // //  
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.